BioWorld
-
AZN regains brazikumab, sells hypertension drugs for $350M+, rolls out Enhertu and Brilinta data
-
Universal T-cell receptor could chase down multiple tumor types
-
Coiled for lucrative strike, Springworks could boost BCMA therapies in MM
-
U.S. drug prices: Is it time to look beyond a binary drug regulatory scheme?
-
Week in review for Jan. 21-24, 2019: Gearing up for Wuhan coronavirus
-
Tazemeto, stat: Accelerated win for Epizyme in ES could ‘reFLect’ well in bigger indication
-
Ipsen puts bone disorder drug dosing on ice after futility analysis
-
Standardized delivery of unique neoantigens improves T-cell vaccines
-
Shortage of MMR vaccine in Mexico deepens on quality issues
BioWorld MedTech
-
Elypta reels in €6.1M to advance liquid biopsy platform
-
Co-Diagnostics completes critical step in developing coronavirus diagnostic
-
Congress not expected to act on patent subject matter eligibility this year
-
Med-tech U.S. IPOs up 40% on average in 2019, with $3B total raised
-
BioWorld MedTech’s Cardiology Extra for Jan. 27, 2020
-
Abbott gets FDA nod for Infinity DBS in Parkinson’s disease, unveils positive data on Proclaim XR
-
Intuitive dips as robotic surgery becomes more mainstream and competition looms
-
Amazon’s Majmudar discusses challenges of getting novel tech to market
-
MDMA’s Leahey: ACA supporters saw device tax as ‘a spreadsheet exercise’
BioWorld Asia
-
Chi-Med’s surufatinib phase III trial halted early after meeting primary endpoint in advanced pancreatic NET
-
China’s I-Mab goes public in targeted range for $103.7M; after-market deep Zai?
-
Industry: Trade agreement important first step toward fairer Chinese market
-
Noxopharm spin-off Nyrada lists on ASX raising AU$8.5 million in oversubscribed IPO
-
Bionetix secures $9.33M in series B funding for AML/MDS and glaucoma treatment
-
Oncologie boosts pipeline with phase II-ready bispecific candidate in Mereo deal
-
Miracogen expands ADC deal with Synaffix
-
China promotes real-world evidence in R&D and approval with new guidelines
-
Aum Biosciences partners with Cyclica for cancer therapies development
